Xeris Biopharma Holdings, Inc. — Cyborg Score 7/10

Strategic Profile

Founded in 2005, Xeris is a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables. Key commercialized products include Recorlev, which ended 2025 with approximately 700 patients; Gvoke, which grew revenue more than 13% compared to prior year; and Keveyis, which finished with a growing patient base.

Cyborg Score Rationale

The company demonstrated strong commercial execution with growing patient bases across key products, sustained Gvoke revenue growth above 13%, and delivered positive Adjusted EBITDA in every quarter of 2025. Recent intellectual property strengthening and analyst day positioning suggest confidence in long-term growth trajectory.

Top Insights

• Commercial-stage biopharmaceutical with three marketed products in high-value endocrine and neurological therapeutic areas
• Recorlev for Cushing's syndrome shows expanding adoption with ~700 patients on therapy
• Achieved positive Adjusted EBITDA in every quarter of 2025, indicating pathway to sustained profitability
• Strengthened intellectual property portfolio with new Orange Book-listed patent for Recorlev, providing long-term competitive protection

Named Competitors

• Specialty Pharma Injectables — Specialty pharmaceuticals and urology-focused therapies
• CNS/Neuro Therapies — Focused on neurological and seizure disorder treatments
• Critical Care Injectables — Specialty injectables for critical care and oncology

Recent Developments

• (January 2026) Expected record Q4 2025 and full-year 2025 total revenue
• (January 2026) Announced inducement grants under NASDAQ listing rules
• (2025) Delivered positive Adjusted EBITDA in every quarter and achieved strategic IP milestones

Open the full interactive Xeris Biopharma Holdings, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.